Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Guanosine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HINT1 | P49773 | 4/20 | 0.65 |
| ▸ | NT5E | P21589 | 1/20 | 0.65 |
| ▸ | HPGD | P15428 | 1/20 | 0.63 |
| ▸ | TGM2 | P21980 | 1/20 | 0.61 |
| ▸ | FUT5 | Q11128 | 1/20 | 0.56 |
| ▸ | KRAS | P01116 | 2/20 | 0.55 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.55 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.55 |
| ▸ | GSK3A | P49840 | 2/20 | 0.55 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.55 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.55 |
| ▸ | PNP | P00491 | 1/20 | 0.55 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Guanosine SCHEMBL27216237 | 1.00 | HINT1 (0.65) | HINT1NT5EHPGDTGM2FUT5 | |
| Guanosine SCHEMBL17845812 | 0.95 | HINT1 (0.64) | HINT1NT5EHPGDTGM2FUT5 | |
| Guanosine SCHEMBL27216236 | 0.95 | HINT1 (0.64) | HINT1NT5EHPGDTGM2FUT5 | |
| Guanosine SCHEMBL376138 | 0.94 | NT5E (0.72) | HINT1NT5EHPGDTGM2FUT5 | |
| Guanosine SCHEMBL94793 | 0.94 | NT5E (0.72) | HINT1NT5EHPGDTGM2FUT5 | |
| Guanosine SCHEMBL1304255 | 0.94 | NT5E (0.72) | HINT1NT5EHPGDTGM2FUT5 | |
| Guanosine SCHEMBL44407 | 0.94 | NT5E (0.72) | HINT1NT5EHPGDTGM2FUT5 | |
| Guanosine SCHEMBL31361372 | 0.94 | NT5E (0.72) | HINT1NT5EHPGDTGM2FUT5 | |
| Guanosine SCHEMBL2589323 | 0.94 | NT5E (0.72) | HINT1NT5EHPGDTGM2FUT5 | |
| Guanosine SCHEMBL8719176 | 0.93 | NT5E (0.70) | HINT1NT5EHPGDTGM2FUT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230183286-A1 | NOVEL 3' END CAPS, 5' END CAPS AND COMBINATIONS THEREOF FOR THERAPEUTIC RNA | NOVARTIS AG (CH) | 2023-06-15 | — | — | US | disclosed |
| WO-2023282245-A1 | METHOD FOR PURIFYING NUCLEOTIDES, DEVICE FOR PURIFYING NUCLEOTIDES, HYDROPHOBIC REAGENT, AND HYDROPHOBIC SUBSTRATE | 国立研究開発法人科学技術振興機構 | 2023-01-12 | — | — | WO | disclosed |
| EP-3904366-A1 | END CAPPED NUCLEIC ACID MOLECULES | Novartis AG (CH) | 2021-11-03 | — | — | EP | disclosed |
| CN-111848712-A | End-capped nucleic acid molecules | 诺华股份有限公司 | 2020-10-30 | — | — | CN | disclosed |
| US-20200190132-A1 | NOVEL 3' END CAPS, 5' END CAPS AND COMBINATIONS THEREOF FOR THERAPEUTIC RNA | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2020-06-18 | — | — | US | disclosed |
| US-10676499-B2 | 3′ end caps, 5′ end caps and combinations thereof for therapeutic RNA | NOVARTIS AG (CH) | 2020-06-09 | — | — | US | disclosed |
| US-20180002368-A1 | NOVEL 3' END CAPS, 5' END CAPS AND COMBINATIONS THEREOF FOR THERAPEUTIC RNA | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2018-01-04 | — | — | US | disclosed |
| EP-3233880-A1 | END CAPPED NUCLEIC ACID MOLECULES | Novartis AG (CH) | 2017-10-25 | — | — | EP | disclosed |
| WO-2016098028-A1 | END CAPPED NUCLEIC ACID MOLECULES | NOVARTIS AG (CH) | 2016-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183286-A1 | NOVEL 3' END CAPS, 5' END CAPS AND COMBINATIONS THEREOF FOR THERAPEUTIC RNA | RNGTT, NSUN2, NSUN3 | HINT1 468/4885NT5E 106/4885HPGD 4849/4885 |
| US-20200190132-A1 | NOVEL 3' END CAPS, 5' END CAPS AND COMBINATIONS THEREOF FOR THERAPEUTIC RNA | RNGTT, NSUN2, NSUN3 | HINT1 468/4885NT5E 106/4885HPGD 4849/4885 |
| US-20180002368-A1 | NOVEL 3' END CAPS, 5' END CAPS AND COMBINATIONS THEREOF FOR THERAPEUTIC RNA | NSUN2, NSUN3, RNGTT | HINT1 589/4885NT5E 151/4885HPGD 4822/4885 |
| US-10676499-B2 | 3′ end caps, 5′ end caps and combinations thereof for therapeutic RNA | RNGTT, NSUN3, NSUN2 | HINT1 560/4885NT5E 83/4885HPGD 4835/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.